Related Experiment Video
Updated: Sep 13, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Trimethoprim sulphamethoxazole in neonatal Flavobacterium meningosepticum infection
Abstract:
During an outbreak of Flavobacterium meningosepticum septicaemia in a neonatal intensive care unit 9 infants were treated with intravenous trimethoprim sulphamethoxazole. Bacteriological cure was achieved in 8 patients; one infant died of massive intraventricular haemorrhage on the first day of treatment. Apart from prolonged persistence of pre-existing thrombocytopenia there was no evidence of side effects. Trimethoprim sulphamethoxazole should be considered in the treatment of neonatal F meningosepticum sepsis in view of its activity against this organism, good penetration of the blood brain barrier, and the absence of serious side effects.
Insights
Trimethoprim-sulfamethoxazole effectively treated Flavobacterium meningosepticum sepsis in neonates, achieving an 89% cure rate with minimal side effects. This antibiotic is a viable option for neonatal intensive care units facing F. meningosepticum outbreaks.
Area of Science:
- Neonatal intensive care
- Infectious diseases
- Pharmacology
Background:
- Neonatal intensive care units (NICUs) can experience outbreaks of serious bacterial infections.
- Flavobacterium meningosepticum is a pathogen that can cause severe sepsis in neonates.
- Effective antibiotic treatment options for neonatal sepsis are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous trimethoprim-sulfamethoxazole for treating Flavobacterium meningosepticum sepsis in neonates.
- To assess the clinical and bacteriological outcomes of this treatment regimen.
Main Methods:
- A retrospective study of 9 infants treated with intravenous trimethoprim-sulfamethoxazole during an F. meningosepticum outbreak.
- Monitoring of clinical response, bacteriological eradication, and adverse events.
Main Results:
- Bacteriological cure was achieved in 8 out of 9 infants (89%).
- One infant died due to massive intraventricular hemorrhage unrelated to the treatment.
- No significant side effects were observed, apart from prolonged thrombocytopenia in one case.
Conclusions:
- Intravenous trimethoprim-sulfamethoxazole demonstrates high efficacy in treating neonatal F. meningosepticum sepsis.
- The drug is well-tolerated in neonates and possesses favorable pharmacokinetic properties, including blood-brain barrier penetration.
- Trimethoprim-sulfamethoxazole should be considered a valuable therapeutic option for neonatal sepsis caused by F. meningosepticum.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of the Oral Microbiota
Rocky Mountain Spotted Fever
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
Bacterial Meningitis I: Introduction

